Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

expertreviewby [‘mediPr]
HER2 Explorer

Hong Kong corner · Section

HER2 Explorer

Recent posts

For registered Hong Kong doctors
Reporting HER2 IHC in 2026: CAP-Aligned Reporting Across Tumor Types and the Impact of Intratumoral HeterogeneityRefining HER2 IHC Assessment Guided by CAP Reporting Template: Enabling Accurate Classification Across Solid Tumors and Addressing Intratumoral HeterogeneityThe use of IHC staining of tissue samples to guide targeted treatment is widely used in clinical practice, and is recommended by expert groups for many tumor types and biomarkers. The classical approach to IHC scoring for biomarkers, such as human epidermal growth factor receptor-2 (HER2), classifies specimens as either ‘positive’ or ‘negative’, scoring samples as IHC0, 1+, 2+ or 3+ per pathologists’ visual interpretation.24 Jun 2026SponsoredHER2 Unraveled—The Vital Distinction Between Overexpression and Gene Amplification in CancerHER2 Unraveled—The Vital Distinction Between Overexpression and Gene Amplification in CancerHuman epidermal growth factor receptor 2 (HER2) is a crucial biomarker in contemporary cancer management. Alterations in the HER2 protein or in the protein-coding gene, erythroblastic leukemia viral oncogene homolog 2 (ERBB2; hereafter referred to as HER2 in line with common practice), have significant clinical implications. Overexpression of the HER2 protein, gene amplification or activating mutations can overactivate or enhance downstream HER2 signaling pathways. Increased HER2 signaling drives key processes in tumorigenesis, including cellular transformation, survival, proliferation, and in11 Dec 2025SponsoredNavigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker AssessmentNavigating HER2 Testing: Unveiling the Strengths and Limitations to Optimize Biomarker AssessmentDue to the availability of human epidermal growth factor receptor 2 (HER2)-directed therapies, testing for HER2 alterations, including overexpression, gene amplification or mutations is recommended in treatment guidelines for various tumor types, including breast cancer, gastric cancer, biliary tract cancer, cervical cancer, colorectal cancer, non-small cell lung cancer (NSCLC), and others.1-1031 Jul 2025SponsoredPrevalence and role of HER2 driver mutations in cancersPrevalence and role of HER2 driver mutations in cancersApart from Human Epidermal Growth Factor Receptor 2 (HER2) gene amplification or receptor protein overexpression (discussed in Article 1 and Article 3), dysregulation of HER2 activity may also be caused by HER2 gene mutations.1 Approximately 90% of the mutations are clustered in the extracellular dimerization domain and intracellular kinase domain, with the remainder occurring within the juxtamembrane or transmembrane domains.14 Apr 2025SponsoredRedefining-HERness-HER2-low-and-ultralow-breast-cancersRedefining HERness: HER2-low and ultralow breast cancersThe 2018 guidelines from the American Society of Clinical Oncology (ASCO) and the College of American Pathology (CAP) classify human epidermal growth factor receptor-2 (HER2) status in breast cancer (BC) according to immunohistochemistry (IHC) staining results of biopsy specimens, ranging from IHC 0 to IHC 3+, plus in situ hybridization (ISH) test results.126 Aug 2024SponsoredHER2 as a biomarker in cancers_0824HER2 as a biomarker in cancersHuman epidermal growth factor receptor-2 (HER2) is a member of the erythroblastic oncogene B (ERBB) family of transmembrane tyrosine kinase receptors that also includes epidermal growth factor receptor (EGFR, also known as HER1), and human epidermal growth factor receptors -3 and -4 (HER3, HER4).1,2 Despite being a receptor, HER2 has no known ligand, but its conformation is similar to the ligand-activated form of other ERBB family members, favoring heterodimerization with them.1,316 Jul 2024Sponsored